PMID- 35070271
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240405
IS  - 2045-7022 (Print)
IS  - 2045-7022 (Electronic)
IS  - 2045-7022 (Linking)
VI  - 12
IP  - 1
DP  - 2022 Jan
TI  - Reducing severe cutaneous adverse and type B adverse drug reactions using 
      pre-stored human leukocyte antigen genotypes.
PG  - e12098
LID - 10.1002/clt2.12098 [doi]
LID - e12098
AB  - BACKGROUND: Several type B adverse drug reactions (ADRs), especially severe 
      cutaneous adverse reactions (SCARs), are associated with particular human 
      leukocyte antigen (HLA) genotypes. However, pre-stored HLA information obtained 
      from other clinical workups has not been used to prevent ADRs. We aimed to 
      simulate the preemptive use of pre-stored HLA information in electronic medical 
      records to evaluate whether this information can prevent ADRs. METHODS: We 
      analyzed the incidence and the risk of ADRs for selected HLA alleles 
      (HLA-B*57:01, HLA-B*58:01, HLA-A*31:01, HLA-B*15:02, HLA-B*15:11, HLA-B*13:01, 
      HLA-B*59:01, and HLA-A*32:01) and seven drugs (abacavir, allopurinol, 
      carbamazepine, oxcarbazepine, dapsone, methazolamide, and vancomycin) using 
      pre-stored HLA information of transplant patients based on the Pharmacogenomics 
      Knowledge Base guidelines and experts' consensus. RESULTS: Among 11,988 
      HLA-tested transplant patients, 4092 (34.1%) had high-risk HLA alleles, 4583 
      (38.2%) were prescribed risk drugs, and 580 (4.8%) experienced type B ADRs. 
      Patients with HLA-B*58:01 had a significantly higher incidence of type B ADR and 
      SCARs associated with allopurinol use than that of patients without HLA-B*58:01 
      (17.2% vs. 11.9%, odds ratio [OR] 1.53 [95% confidence interval CI 1.09-2.13], 
      p = 0.001, 2.3% versus 0.3%, OR 7.13 [95% CI 2.19-22.69], p < 0.001). Higher 
      risks of type B ADR and SCARs were observed in patients taking carbamazepine or 
      oxcarbazepine if they had one of HLA-A*31:01, HLA-B*15:02, or HLA-B*15:11 
      alleles. Vancomycin and dapsone use in HLA-A*32:01 and HLA-B*13:01 carriers, 
      respectively, showed trends toward increased risk of type B ADRs. CONCLUSION: 
      Utilization of pre-stored HLA data can prevent type B ADRs including SCARs by 
      screening high-risk patients.
CI  - (c) 2022 The Authors. Clinical and Translational Allergy published by John Wiley & 
      Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
FAU - Lee, Kye Hwa
AU  - Lee KH
AUID- ORCID: 0000-0002-7593-7020
AD  - Department of Information Medicine Asan Medical Center Seoul South Korea.
FAU - Kang, Dong Yoon
AU  - Kang DY
AUID- ORCID: 0000-0003-4283-2633
AD  - Drug Safety Center Seoul National University Hospital Seoul South Korea.
FAU - Kim, Hyun Hwa
AU  - Kim HH
AUID- ORCID: 0000-0003-4496-6328
AD  - Drug Safety Center Seoul National University Hospital Seoul South Korea.
FAU - Kim, Yi Jun
AU  - Kim YJ
AUID- ORCID: 0000-0002-1763-4267
AD  - Institute of Convergence Medicine Ewha Womans University Mokdong Hospital Seoul 
      South Korea.
FAU - Kim, Hyo Jung
AU  - Kim HJ
AUID- ORCID: 0000-0001-9555-0926
AD  - Department of Digital Health Samsung Advanced Institute for Health Science and 
      Technology Sungkyunkwan University Seoul South Korea.
FAU - Kim, Ju Han
AU  - Kim JH
AUID- ORCID: 0000-0003-1522-9038
AD  - Seoul National University Biomedical Informatics and Systems Biomedical 
      Informatics Research Center Division of Biomedical Informatics Seoul National 
      University College of Medicine Seoul South Korea.
FAU - Song, Eun Young
AU  - Song EY
AUID- ORCID: 0000-0003-1286-9611
AD  - Department of Molecular Medicine and Biopharmaceutical Sciences Graduate School 
      of Convergence Science and Technology and College of Medicine Medical Research 
      Center Seoul National University Seoul South Korea.
FAU - Yun, James
AU  - Yun J
AUID- ORCID: 0000-0002-3482-5663
AD  - Department of Immunology and Rheumatology Nepean Hospital Sydney New South Wales 
      Australia.
AD  - Faculty of Medicine and Health The University of Sydney Sydney New South Wales 
      Australia.
FAU - Kang, Hye-Ryun
AU  - Kang HR
AUID- ORCID: 0000-0002-2317-4201
AD  - Drug Safety Center Seoul National University Hospital Seoul South Korea.
AD  - Institute of Allergy and Clinical Immunology Seoul National University Medical 
      Research Center Seoul National University College of Medicine Seoul South Korea.
LA  - eng
PT  - Journal Article
DEP - 20220114
PL  - England
TA  - Clin Transl Allergy
JT  - Clinical and translational allergy
JID - 101576043
PMC - PMC8760506
OTO - NOTNLM
OT  - adverse drug reaction
OT  - human leukocyte antigen
OT  - hypersensitivity
OT  - pharmacogenomics
OT  - preemptive genotyping
COIS- The authors have declared no conflicts of interest.
EDAT- 2022/01/25 06:00
MHDA- 2022/01/25 06:01
PMCR- 2022/01/14
CRDT- 2022/01/24 08:51
PHST- 2021/06/01 00:00 [received]
PHST- 2021/11/26 00:00 [revised]
PHST- 2021/12/21 00:00 [accepted]
PHST- 2022/01/24 08:51 [entrez]
PHST- 2022/01/25 06:00 [pubmed]
PHST- 2022/01/25 06:01 [medline]
PHST- 2022/01/14 00:00 [pmc-release]
AID - CLT212098 [pii]
AID - 10.1002/clt2.12098 [doi]
PST - epublish
SO  - Clin Transl Allergy. 2022 Jan 14;12(1):e12098. doi: 10.1002/clt2.12098. 
      eCollection 2022 Jan.